Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head trial.

The American College of Physicians (ACP) has developed new recommendations to prevent episodic migraines in nonpregnant ...

The ACP guideline, published in Annals of Internal Medicine, includes three recommendations centered around monotherapy: ...

Migraine is a common neurological syndrome that affects approximately 10–20% of the population. The pathophysiology of migraine is unclear. 5-hydroxytriptamine is a key mediator in the ...

The Clinical Guidelines Committee of the American College of Physicians (ACP) has released a new clinical guideline on the ...

It may also serve as a reference for the therapeutic strategy since it is higher in patients requiring migraine prevention and responsive to short-term topiramate treatment. These results are ...

The ACP issued new clinical guidance on preventing episodic migraines, classified as one to 14 headache days per month, in ...

With historical data showing migraine to be underdiagnosed and undertreated, new guidance from the American College of ...

or topiramate. Gemma Jolly of medical charity the Migraine Trust said NICE’s recommendation is “wonderful news for people living with this very painful and debilitating neurological condition ...